[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021; 71, 209−49. doi:  10.3322/caac.21660
[2] Washington MK, Goldberg RM, Chang GJ, et al. Diagnosis of digestive system tumours. Int J Cancer, 2021; 148, 1040−50. doi:  10.1002/ijc.33210
[3] Zhang YY, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature, 1994; 372, 425−32. doi:  10.1038/372425a0
[4] Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol, 2006; 6, 772−83. doi:  10.1038/nri1937
[5] Abella V, Scotece M, Conde J, et al. Leptin in the interplay of inflammation, metabolism and immune system disorders. Nat Rev Rheumatol, 2017; 13, 100−9. doi:  10.1038/nrrheum.2016.209
[6] Friedman JM. Leptin and the endocrine control of energy balance. Nat Metab, 2019; 1, 754−64. doi:  10.1038/s42255-019-0095-y
[7] Marques V, Arella F, Afonso MB, et al. Decoding the role of leptin and adiponectin in obesity-related gastrointestinal cancer. Clin Sci, 2023; 137, 1095−114. doi:  10.1042/CS20230411
[8] Ghilardi N, Ziegler S, Wiestner A, et al. Defective STAT signaling by the leptin receptor in diabetic mice. Proc Natl Acad Sci USA, 1996; 93, 6231−5. doi:  10.1073/pnas.93.13.6231
[9] Ghasemi A, Saeidi J, Azimi-Nejad M, et al. Leptin-induced signaling pathways in cancer cell migration and invasion. Cell Oncol, 2019; 42, 243−60. doi:  10.1007/s13402-019-00428-0
[10] Spyrou N, Avgerinos KI, Mantzoros CS, et al. Classic and novel adipocytokines at the intersection of obesity and cancer: diagnostic and therapeutic strategies. Curr Obes Rep, 2018; 7, 260−75. doi:  10.1007/s13679-018-0318-7
[11] Philips RL, Wang YX, Cheon H, et al. The JAK-STAT pathway at 30: much learned, much more to do. Cell, 2022; 185, 3857−76. doi:  10.1016/j.cell.2022.09.023
[12] Matsuoka N, Ogawa Y, Hosoda K, et al. Human leptin receptor gene in obese Japanese subjects: evidence against either obesity-causing mutations or association of sequence variants with obesity. Diabetologia, 1997; 40, 1204−10. doi:  10.1007/s001250050808
[13] Domingos PLB, Farias LC, Pereira CS, et al. Leptin receptor polymorphism Gln223Arg (rs1137101) in oral squamous cell carcinoma and potentially malignant oral lesions. Springerplus, 2014; 3, 683. doi:  10.1186/2193-1801-3-683
[14] Hussain SR, Naqvi H, Gupta S, et al. A study on oncogenic role of leptin and leptin receptor in oral squamous cell. Tumour Biol, 2015; 36, 6515−23. doi:  10.1007/s13277-015-3342-1
[15] Rodrigues PRS, Maia LL, Santos M, et al. Leptin receptor expression and Gln223Arg polymorphism as prognostic markers in oral and oropharyngeal cancer. Genet Mol Res, 2015; 14, 14979−88. doi:  10.4238/2015.November.24.5
[16] Hung WC, Tsai CM, Lin CW, et al. Leptin -2548 G/A polymorphisms are associated to clinical progression of oral cancer and sensitive to oral tumorization in nonsmoking population. J Cell Biochem, 2019; 120, 15145−56. doi:  10.1002/jcb.28776
[17] Doecke JD, Zhao ZZ, Stark MS, et al. Single nucleotide polymorphisms in obesity-related genes and the risk of esophageal cancers. Cancer Epidemiol Biomarkers Prev, 2008; 17, 1007−12. doi:  10.1158/1055-9965.EPI-08-0023
[18] Qiu H, Lin XT, Tang WF, et al. Investigation of TCF7L2, LEP and LEPR polymorphisms with esophageal squamous cell carcinomas. Oncotarget, 2017; 8, 109107−19. doi:  10.18632/oncotarget.22619
[19] Ren XH, Jiang YB. Study on relationship between Gln223Arg variant in leptin receptor gene and gastric cancer. Chin J Health Lab Technol, 2010; 20, 806−7. (In Chinese
[20] Pan H. Studies on association of the overweight/obesity, helicobacter pylori infection and gastric cancer. Lanzhou University, 2014. (In Chinese
[21] Ling W. The study on leptin receptor gene polymorphsims and environmental factors interaction associated with the susceptibility of gastric cancer. Wuhan University, 2016. (In Chinese
[22] Chia VM, Newcomb PA, Lampe JW, et al. Leptin concentrations, leptin receptor polymorphisms, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev, 2007; 16, 2697−703. doi:  10.1158/1055-9965.EPI-07-0467
[23] Pechlivanis S, Bermejo JL, Pardini B, et al. Genetic variation in adipokine genes and risk of colorectal cancer. Eur J Endocrinol, 2009; 160, 933−40. doi:  10.1530/EJE-09-0039
[24] Vašků A, Vokurka J, Bienertová-Vašků J. Obesity-related genes variability in Czech patients with sporadic colorectal cancer: preliminary results. Int J Colorectal Dis, 2009; 24, 289−94. doi:  10.1007/s00384-008-0553-6
[25] Karimi K, Arkani M, Safaei A, et al. Association of leptin receptor gene Gln223Arg polymorphism with susceptibility to colorectal cancer. Gastroenterol Hepatol Bed Bench, 2011; 4, 192−8.
[26] Mahmoudi T, Farahani H, Nobakht H, et al. Genetic Variations in Leptin and Leptin receptor and Susceptibility to colorectal cancer and obesity. Iran J Cancer Prev, 2016; 9, e7013.
[27] Lin J, Xie ZQ, Lan B, et al. Investigation of Leptin and its receptor (LEPR) for single nucleotide polymorphisms in colorectal cancer: a case-control study involving 2, 306 subjects. Am J Transl Res, 2020; 12, 3613−28.
[28] Li Z, Yuan WT, Ning SJ, et al. Role of leptin receptor (LEPR) gene polymorphisms and haplotypes in susceptibility to hepatocellular carcinoma in subjects with chronic hepatitis B virus infection. Mol Diagn Ther, 2012; 16, 383−8. doi:  10.1007/s40291-012-0008-1
[29] Zhang S, Jiang JK, Chen Z, et al. Investigation of LEP and LEPR polymorphisms with the risk of hepatocellular carcinoma: a case-control study in Eastern Chinese Han population. Onco Targets Ther, 2018; 11, 2083−9. doi:  10.2147/OTT.S153931
[30] Karam HA, Bessa SS, Ali EMM, et al. The Inter-Relation between leptin receptor (Q223R) Gene Polymorphism and the risk of Egyptian patients with HCC. Asian Pac J Cancer Prev, 2020; 21, 3557−65. doi:  10.31557/APJCP.2020.21.12.3557
[31] Tang YZ, Zhan LL, Lu Y, et al. Association of LEPR gene polymorphisms with the risk of hepatitis B virus-related liver disease in Guangxi Chinese: a case-control study. Infect Genet Evol, 2020; 84, 104366. doi:  10.1016/j.meegid.2020.104366
[32] Li L, Meng XC, Liu LY, et al. Single-nucleotide polymorphisms in LEP and LEPR associated with breast cancer risk: results from a multicenter case-control study in Chinese females. Front Oncol, 2022; 12, 809570. doi:  10.3389/fonc.2022.809570
[33] Bieńkiewicz J, Romanowicz H, Wilczyński M, et al. Association of single nucleotide polymorphism LEP-R c. 668A>G (p. Gln223Arg, rs1137101) of leptin receptor gene with endometrial cancer. BMC cancer, 2021; 21, 925. doi:  10.1186/s12885-021-08620-y
[34] Unsal M, Kara N, Karakus N, et al. Effects of leptin and leptin receptor gene polymorphisms on lung cancer. Tumour Biol, 2014; 35, 10231−6. doi:  10.1007/s13277-014-2293-2
[35] He J, Xi B, Ruiter R, et al. Association of LEP G2548A and LEPR Q223R polymorphisms with cancer susceptibility: evidence from a meta-analysis. PLoS One, 2013; 8, e75135. doi:  10.1371/journal.pone.0075135
[36] Liu PC, Shi H, Liu R, et al. Lack of association between LEPR Q223R polymorphisms and cancer susceptibility: evidence from a meta-analysis. J BUON, 2014; 19, 855−62.
[37] Rong GX, Tang WF, Wang YF, et al. Investigation of leptin receptor rs1137101 G>A polymorphism with cancer risk: evidence from 35936 subjects. Biosci Rep, 2019; 39, BSR20182240. doi:  10.1042/BSR20182240
[38] Lu XL, Liu MT, Liao YX, et al. Meta-analysis of the association between mTORC1-related genes polymorphisms and cancer risk. Pathol Res Pract, 2022; 229, 153696. doi:  10.1016/j.prp.2021.153696
[39] Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol, 2018; 15, 234−48. doi:  10.1038/nrclinonc.2018.8
[40] Bjørbæk C, Buchholz RM, Davis SM, et al. Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem, 2001; 276, 4747−55. doi:  10.1074/jbc.M007439200
[41] Zhu SL, Tang ZY, Tang Y, et al. Correlation of Q223R and K109R polymorphisms in leptin receptor gene with susceptibility of breast cancer: a systematic review and meta-analysis. J Chin Med Assoc, 2023; 86, 549−56. doi:  10.1097/JCMA.0000000000000918